Skip to main content

Table 4 Patients with endoscopic inflammation involvement

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic

High-risk featuresa

N = 71

No high-risk features

N = 111

P value

Duration of symptoms (days, SD)

41 (106)

27 (60)

0.301

IV steroids, n (%)

41 (66.1)

42 (58.3)

0.378

Infliximab/vedolizumab, n (%)

30 (46.2)

12 (15.8)

< 0.001

Mean duration from diagnosis to first recurrence (days, SD)

140 (147)

144 (121)

0.902

Outcomes, n (%)

 Hospitalization

58 (81.7)

74 (66.7)

0.028

 Duration of hospitalization (days, SD)

9 (8)

6 (5)

0.016

 ICU admission

3 (4.2)

4 (3.6)

0.656

 Recurrence

20 (28.2)

31 (27.9)

1.000

 Repeat endoscopy

18 (25.4)

18 (16.2)

0.181

  1. aHigh-risk endoscopic features; deep ulcers > 2 mm in depth, large ulcers > 1 cm, extensive involvement